Compare · Research-Use-Only
Compare research peptides
Side-by-side mechanism, molecular spec, and published-research comparisons. Pick a matchup below or browse the full catalog.
BPC-157 vs GHK-Cu
The two most-cited recovery peptides. BPC-157 modulates growth factor pathways; GHK-Cu is a copper chaperone influencing collagen synthesis.
Ipamorelin vs Ipamorelin / CJC-1295
One selective ghrelin-receptor peptide vs a two-peptide blend that adds a short-acting GHRH analog acting on a second receptor.
Retatrutide vs Tirzepatide
Dual GIP/GLP-1 agonist (Tirzepatide, SURMOUNT-1) versus the triple-agonist Retatrutide with added glucagon receptor activity (Phase 2, NEJM).
Tesamorelin vs Ipamorelin
GHRH analog vs ghrelin-mimetic. Different upstream targets, overlapping downstream GH and IGF-1 effects in research models.
BPC-157 vs TB-500
The classic recovery pairing, and the most frequently confused. Growth factor modulation vs actin sequestration, plus what TB-500 actually is.
CJC-1295 (DAC) vs Ipamorelin / CJC-1295
DAC vs no-DAC is not a formulation detail, it is a different molecule. Days-long albumin binding vs an hours-long pulsatile profile.
Cagrilintide vs Tirzepatide
Incretin agonism vs amylin analog. Different receptor families, different trial programs, and no head-to-head trial between them.
Semax vs Selank
Grouped constantly, mechanistically unrelated. ACTH fragment and neurotrophin expression vs tuftsin derivative and GABAergic modulation.
Epithalon vs NAD+
Both appear in longevity research, with very different evidence bases. Telomerase induction from a narrow literature vs a core metabolic cofactor.
AOD-9604 vs 5-Amino-1MQ
A GH fragment that missed its Phase IIb endpoint vs a small-molecule NNMT inhibitor that is not a peptide. Read the evidence carefully on both.
Melanotan II vs PT-141 (Bremelanotide)
Two near-identical cyclic alpha-MSH analogs. One C-terminal difference, and a very different trial and regulatory record.
CJC-1295 (DAC) vs Tesamorelin
Two GHRH analogs, one receptor. An albumin-tethered GHRH(1-29) analog vs a modified GHRH approved by the FDA as Egrifta.
TB-500 vs GHK-Cu
An actin-binding fragment of thymosin beta-4 vs a natural copper-carrying tripeptide, and whose evidence was generated with which molecule.
MOTS-c vs NAD+
A mitochondrial-encoded signalling peptide vs the cell's core redox cofactor. Both mitochondrial, mechanistically unrelated.
KPV vs BPC-157
A three-residue alpha-MSH fragment that works through PepT1 vs a 15-residue gastric peptide. Both studied in gut models, both preclinical.
Looking for a specific comparison?
Request a side-by-side in our Discord community. We add new comparisons based on what researchers ask about most.
Browse all compounds →